Blood Drug Testing

희망적인 유전자 치료

Summary: Biotech s bright hope Scientists are newly optimistic that gene therapy will help fight the most serious diseases By Linda Marsa Special to The Times August 28 2006 TO the shrill whine of a high speed drill neurosurgeon Dr Paul Larson makes two nickel sized holes in Shirley Cooper s skull Guided by a computerized MRI map he plunges a long thin needle through one hole and deep into the brain and empties the syringe A very special payload trickles into her brain genes that if all goes well will help her control the movement of her muscles It is a day in late May and Cooper 60 an artist who lives near Seattle has come to the UC San Francisco Medical Center to find some relief from the Parkinson s disease that is stealing her identity Without medication she has trouble walking and talking and can t hold a paint brush And the drugs are wearing off as they eventually do for all Parkinson s patients After that she probably will deteriorate rapidly The experimental treatment Cooper is undergoing is intended to reverse that process Parkinson s destroys cells in the brain that make dopamine and the loss of this key brain transmitter triggers the disease s crippling symptoms tremors in the arms legs and face stiff or frozen limbs and impaired balance and coordination In the trial she s involved in the earliest of clinical tests designed to assess safety scientists have engineered a harmless stripped down virus to carry a gene that will boost brain dopamine through the enzyme it encodes amino acid decarboxylase or AADC When the virus is injected into her brain they hope the gene will be incorporated into healthy brain cells and steadily produce the enzyme Gene therapy is making a comeback after a series of serious setbacks that threatened to permanently derail human tests In recent years European scientists have cured more than two dozen patients suffering from three rare and in some cases lethal immune disorders Spurred by this success plus the development of new techniques aimed at making the therapy safer and more effective more than 300 gene therapy trials including the one for Parkinson s at UC San Francisco are underway in the U S and abroad The approaches include what people traditionally think of as gene therapy inserting functional genes to replace single faulty ones to treat relatively rare genetic diseases such as muscular dystrophy cystic fibrosis sickle cell anemia beta thalassemia and hemophilia But more and more gene therapy is being studied as a treatment for lethal ills that are not inherited in any clear simple way cancer hepatitis AIDS heart disease and which also plague millions Today scientists are injecting genes into people to try to block the formation of deadly cancerous tumors They re implanting genes that stimulate cell growth in an attempt to regenerate heart muscle cells and grow blood vessels in patients with congestive heart failure halt disease progression in people with macular degeneration and slow the death of brain cells in Alzheimer s as well as Parkinson s patients Though most of these treatments are still in the early phases of human tests a gene therapy drug to combat cancer could be available within the year See related story There is genuine excitement in the field says Dr Ronald Crystal a gene therapy pioneer and chairman of the department of genetic medicine at Weill Medical College of Cornell University in New York Gene therapy he predicts will evolve into a major therapeutic method Progress amid trials Today s upbeat mood is in stark contrast to the gloom that pervaded the field in the late 1990s After the rise of genetic engineering in the late 70s gene therapy had been touted as a magic bullet that would quickly fix an array of debilitating and often fatal inherited ills It was nowhere near that simple The first human trial was performed in September 1990 at the National Institutes of Health in Bethesda Md on a young girl suffering from a rare genetic disease called ADA SCID in which the immune system doesn t function properly Healthy versions of the ADA SCID gene were successfully added to the girl s blood cells but she was still taking medication for her condition and doctors couldn t conclude that the gene was providing any benefit Even so it was a breakthrough to show that genes could be added to the body and in the wake of that pioneering experiment more than 450 gene therapy tests were launched involving 4 000 volunteers Not one of those tests cured anyone according to a 1995 National Institutes of Health report that was commissioned to determine where the field stood scientifically More damningly the report concluded that the technology had been tainted by hype leading to the mistaken and widespread perception that gene therapy is further developed and more successful than it actually is the report stated Scientists had been stymied by a host of unanticipated technological problems They didn t know how to get the genes to the sites in the body where they would do any good They didn t know how to make those genes function properly even if they got to intended sites The concept was so simple but some of these barriers were tougher to overcome than people originally thought says Dr Mark A Kay a geneticist at the Stanford University School of Medicine in Palo Alto Part of the problem was that researchers used a scattershot method of delivery Millions of genes were infused into patients through the bloodstream in the hope that enough genes would land where they were needed However even when the genes were incorporated into the right cells which didn t happen very often their effects were only transitory After a couple of weeks they d stop working And the carriers used to ferry genes inside cells sometimes caused problems Because naked pieces of DNA can t penetrate cell membranes scientists generally insert copies of the genes into viruses which can easily enter cells The viruses and scientists have used various types are stripped of their genes so they cannot reproduce or cause disease but as researchers soon discovered they can still elicit an immune response In a 1993 experiment for example scientists successfully added good genes to airway cells in the lungs of 10 patients suffering from the lethal inherited disorder cystic fibrosis But the effect was short lived After a week or two the patients immune system recognized the virus particles as foreign and eliminated the cells says Crystal who conducted these experiments Then in 1999 an 18 year old volunteer in a gene therapy test at the University of Pennsylvania died after a fatal immune reaction to the modified virus used in the trial The incident cast a pall over the field and funding for research dried up The U S Food and Drug Administration halted several other trials and increased its oversight requiring far more stringent monitoring and documentation Yet the trials did continue Success when it finally came was tempered with sadness In trials in France and Britain scientists successfully corrected the genetic mistake causing X SCID which leaves sufferers with no infection fighting white blood cells in 11 young boys But between 2002 and 2005 three of the French boys developed a leukemia like disease Though the boys had been cured of their genetic disease the inserted DNA had inadvertently switched on a cancer causing gene One of the children later died of complications from the leukemia treatment In the wake of this disaster dozens of gene therapy trials that employed the same approach using retroviruses to carry genes into blood producing stem cells were shut down temporarily in the U S and other countries We were on and off hold for almost two years says Dr Donald Kohn a gene therapy pioneer at Childrens Hospital Los Angeles who is in the midst of a similar study in children with ADA SCID Researchers scrambled to uncover what had caused the leukemia They tried to find better ways to safely transport genes to the right parts of the body without accidentally turning on other genes or triggering an immune reaction And they tried to improve the chance that cells once genes were added would continuously secrete therapeutic doses of the desired compounds Though there s still much to be done in all these fronts significant progress has been made scientists say In Europe for example the gene therapy protocols that caused leukemia in the children have been modified by adding chemotherapy That stops the dangerous overproduction of white blood cells And researchers have improved their ability to control the genes that they insert restricting the genes activities to only certain types of cells and allowing them to remain active longer Scientists are also using safer viral transporters that are less likely to turn cells cancerous or trigger immune responses One crucial advance is the development of a new gene transporter based on a family of harmless viruses known as adeno associated virus or AAV They ve become popular DNA vehicles because first of all AAV viruses don t trigger an adverse immune response But another benefit is that AAV comes in different types that home in on different cells For example one form of AAV has an affinity for nerve cells another is attracted to the liver while yet a third type targets muscle cells This means that scientists can select the AAV transporter based on where they want their gene to end up and it will go directly to the right place in the body says Dr Michael Kaplitt a neurosurgeon at Weill Medical College who helped develop the AAV vectors Advances in imaging technology also make it easier to narrowly target therapies Instead of flooding the bloodstream with millions of genes researchers can inject small amounts of genetic materia Biotech s bright hope Scientists are newly optimistic that gene therapy will help fight the most serious diseases By Linda Marsa Special to The Times August 28 2006 TO the shrill whine of a high speed drill neurosurgeon Dr Paul Larson makes two nickel sized holes in Shirley Cooper s skull Guided by a computerized MRI map he plunges a long thin needle through one hole and deep into the brain and empties the syringe A very special payload trickles into her brain genes that if all goes well will help her control the movement of her muscles It is a day in late May and Cooper 60 an artist who lives near Seattle has come to the UC San Francisco Medical Center to find some relief from the Parkinson s disease that is stealing her identity Without medication she has trouble walking and talking and can t hold a paint brush And the drugs are wearing off as they eventually do for all Parkinson s patients After that she probably will deteriorate rapidly The experimental treatment Cooper is undergoing is intended to reverse that process Parkinson s destroys cells in the brain that make dopamine and the loss of this key brain transmitter triggers the disease s crippling symptoms tremors in the arms legs and face stiff or frozen limbs and impaired balance and coordination In the trial she s involved in the earliest of clinical tests designed to assess safety scientists have engineered a harmless stripped down virus to carry a gene that will boost brain dopamine through the enzyme it encodes amino acid decarboxylase or AADC When the virus is injected into her brain they hope the gene will be incorporated into healthy brain cells and steadily produce the enzyme Gene therapy is making a comeback after a series of serious setbacks that threatened to permanently derail human tests In recent years European scientists have cured more than two dozen patients suffering from three rare and in some cases lethal immune disorders Spurred by this success plus the development of new techniques aimed at making the therapy safer and more effective more than 300 gene therapy trials including the one for Parkinson s at UC San Francisco are underway in the U S and abroad The approaches include what people traditionally think of as gene therapy inserting functional genes to replace single faulty ones to treat relatively rare genetic diseases such as muscular dystrophy cystic fibrosis sickle cell anemia beta thalassemia and hemophilia But more and more gene therapy is being studied as a treatment for lethal ills that are not inherited in any clear simple way cancer hepatitis AIDS heart disease and which also plague millions Today scientists are injecting genes into people to try to block the formation of deadly cancerous tumors They re implanting genes that stimulate cell growth in an attempt to regenerate heart muscle cells and grow blood vessels in patients with congestive heart failure halt disease progression in people with macular degeneration and slow the death of brain cells in Alzheimer s as well as Parkinson s patients Though most of these treatments are still in the early phases of human tests a gene therapy drug to combat cancer could be available within the year See related story There is genuine excitement in the field says Dr Ronald Crystal a gene therapy pioneer and chairman of the department of genetic medicine at Weill Medical College of Cornell University in New York Gene therapy he predicts will evolve into a major therapeutic method Progress amid trials Today s upbeat mood is in stark contrast to the gloom that pervaded the field in the late 1990s After the rise of genetic engineering in the late 70s gene therapy had been touted as a magic bullet that would quickly fix an array of debilitating and often fatal inherited ills It was nowhere near that simple The first human trial was performed in September 1990 at the National Institutes of Health in Bethesda Md on a young girl suffering from a rare genetic disease called ADA SCID in which the immune system doesn t function properly Healthy versions of the ADA SCID gene were successfully added to the girl s blood cells but she was still taking medication for her condition and doctors couldn t conclude that the gene was providing any benefit Even so it was a breakthrough to show that genes could be added to the body and in the wake of that pioneering experiment more than 450 gene therapy tests were launched involving 4 000 volunteers Not one of those tests cured anyone according to a 1995 National Institutes of Health report that was commissioned to determine where the field stood scientifically More damningly the report concluded that the technology had been tainted by hype leading to the mistaken and widespread perception that gene therapy is further developed and more successful than it actually is the report stated Scientists had been stymied by a host of unanticipated technological problems They didn t know how to get the genes to the sites in the body where they would do any good They didn t know how to make those genes function properly even if they got to intended sites The concept was so simple but some of these barriers were tougher to overcome than people originally thought says Dr Mark A Kay a geneticist at the Stanford University School of Medicine in Palo Alto Part of the problem was that researchers used a scattershot method of delivery Millions of genes were infused into patients through the bloodstream in the hope that enough genes would land where they were needed However even when the genes were incorporated into the right cells which didn t happen very often their effects were only transitory After a couple of weeks they d stop working And the carriers used to ferry genes inside cells sometimes caused problems Because naked pieces of DNA can t penetrate cell membranes scientists generally insert copies of the genes into viruses which can easily enter cells The viruses and scientists have used various types are stripped of their genes so they cannot reproduce or cause disease but as researchers soon discovered they can still elicit an immune response In a 1993 experiment for example scientists successfully added good genes to airway cells in the lungs of 10 patients suffering from the lethal inherited disorder cystic fibrosis But the effect was short lived After a week or two the patients immune system recognized the virus particles as foreign and eliminated the cells says Crystal who conducted these experiments Then in 1999 an 18 year old volunteer in a gene therapy test at the University of Pennsylvania died after a fatal immune reaction to the modified virus used in the trial The incident cast a pall over the field and funding for research dried up The U S Food and Drug Administration halted several other trials and increased its oversight requiring far more stringent monitoring and documentation Yet the trials did continue Success when it finally came was tempered with sadness In trials in France and Britain scientists successfully corrected the genetic mistake causing X SCID which leaves sufferers with no infection fighting white blood cells in 11 young boys But between 2002 and 2005 three of the French boys developed a leukemia like disease Though the boys had been cured of their genetic disease the inserted DNA had inadvertently switched on a cancer causing gene One of the children later died of complications from the leukemia treatment In the wake of this disaster dozens of gene therapy trials that employed the same approach using retroviruses to carry genes into blood producing stem cells were shut down temporarily in the U S and other countries We were on and off hold for almost two years says Dr Donald Kohn a gene therapy pioneer at Childrens Hospital Los Angeles who is in the midst of a similar study in children with ADA SCID Researchers scrambled to uncover what had caused the leukemia They tried to find better ways to safely transport genes to the right parts of the body without accidentally turning on other genes or triggering an immune reaction And they tried to improve the chance that cells once genes were added would continuously secrete therapeutic doses of the desired compounds Though there s still much to be done in all these fronts significant progress has been made scientists say In Europe for example the gene therapy protocols that caused leukemia in the children have been modified by adding chemotherapy That stops the dangerous overproduction of white blood cells And researchers have improved their ability to control the genes that they insert restricting the genes activities to only certain types of cells and allowing them to remain active longer Scientists are also using safer viral transporters that are less likely to turn cells cancerous or trigger immune responses One crucial advance is the development of a new gene transporter based on a family of harmless viruses known as adeno associated virus or AAV They ve become popular DNA vehicles because first of all AAV viruses don t trigger an adverse immune response But another benefit is that AAV comes in different types that home in on different cells For example one form of AAV has an affinity for nerve cells another is attracted to the liver while yet a third type targets muscle cells This means that scientists can select the AAV transporter based on where they want their gene to end up and it will go directly to the right place in the body says Dr Michael Kaplitt a neurosurgeon at Weill Medical College who helped develop the AAV vectors Advances in imaging technology also make it easier to narrowly target therapies Instead of flooding the bloodstream with millions of genes researchers can inject small amounts of genetic materia

Image Dimensions: 273 x 359